Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Current FDA concern The FDA says compounded AOD-9604 may carry immunogenicity risks for some routes and may have problems linked to peptide impurities and product characterization
British Journal of Haematology , 166(4), 496-513.
Community research plans now often model subcutaneous amounts, but no approved clinical protocol or published human pharmacokinetic study has established those subcutaneous amounts
Contrast that with a patient eating a varied omnivorous diet with no B12 risk factors who receives the same formulation
US$ 20.90
US$ 27.33
US$ 20.72
US$ 26.44
US$ 22.70
US$ 23.42
US$ 24.38
